Concert Pharmaceuticals, Inc Earning Date (CNCE)

USA |NASDAQ |USD

CNCE Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 3, 2022 Jun 2022 - - $0.16
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 3, 2022 Jun 2022 - - $32.02M

Concert Pharmaceuticals, Inc's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 2022.

CNCE Earnings Date & History Chart

CNCE Earnings & Revenue Forecast

CNCE Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 6 $-2.91 $-3.49 $-1.96

CNCE Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 1 / 0 $-3.08 $-3.08 $-3.08

CNCE Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 5 $4.51M $0.00 $20.00M

CNCE Earnings Date & Revenue History

CNCE Earnings History

|
Show More
Show More

CNCE Revenue History

|
Show More
Show More

Concert Pharmaceuticals, Inc Next Earnings Date & Report

CNCE Next Earnings Date & Report Preview: Jun 2022 (FQ)

CNCE's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 30, 2022.

Concert Pharmaceuticals, Inc Previous Earnings Dates & Reports

CNCE Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Concert Pharmaceuticals, Inc's previous earnings date was May 2, 2022 for its fiscal quarter ended Mar 31, 2022.

CNCE Previous Earnings Date & Report Recap: Dec 2021 (FY)

Concert Pharmaceuticals, Inc's previous annual earnings date was Mar 3, 2022 for its fiscal year ended Dec 31, 2021.

CNCE's earnings per share (EPS) was $-2.30, missing the consensus analysts forecast of $-2.05 by 12.20% , and higher than the previous year's EPS (Dec 2020) by -4.17%.

Revenues were $32.58K, worse than the forecast of $32.67M by -99.90%, and down by -99.59% from previous year's revenue.

The company reported a net income of $-80.05K.

Concert Pharmaceuticals, Inc reported a free cash flow of $-55.41M for its fiscal year, compared to $-69.25M a year ago.

The company ended the fiscal year with $1.16M in total debt, a decrease of -92.78% compared to the previous year.